Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer | Zendy

Matthew Smith | Zendy; Blair Egerdie | Zendy; Narciso Hernández Toriz | Zendy; Robert Feldman | Zendy; Teuvo L.J. Tammela | Zendy; Fred Saad | Zendy; Jiří Heráček | Zendy; Maciej Szwedowski | Zendy; Chunlei Ke | Zendy; Amy Kupic | Zendy; Benjamin Z. Leder | Zendy; Carsten Goessl | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

Author(s) -

Matthew Smith,

Blair Egerdie,

Narciso Hernández Toriz,

Robert Feldman,

Teuvo L.J. Tammela,

Fred Saad,

Jiří Heráček,

Maciej Szwedowski,

Chunlei Ke,

Amy Kupic,

Benjamin Z. Leder,

Carsten Goessl

Publication year - 2009

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa0809003

Subject(s) - medicine , denosumab , bone mineral , femoral neck , androgen deprivation therapy , prostate cancer , urology , placebo , osteoporosis , bone density , surgery , cancer , pathology , alternative medicine

Androgen-deprivation therapy is well-established for treating prostate cancer but is associated with bone loss and an increased risk of fracture. We investigated the effects of denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor-kappaB ligand, on bone mineral density and fractures in men receiving androgen-deprivation therapy for nonmetastatic prostate cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research